Mangoceuticals, Inc.
MGRX
$2.14
-$0.19-8.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 516.00K | 511.10K | 615.90K | 755.10K | 866.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 516.00K | 511.10K | 615.90K | 755.10K | 866.90K |
| Cost of Revenue | 201.20K | 216.40K | 235.90K | 312.60K | 362.50K |
| Gross Profit | 314.80K | 294.70K | 380.00K | 442.50K | 504.40K |
| SG&A Expenses | 12.08M | 9.02M | 7.90M | 8.54M | 8.64M |
| Depreciation & Amortization | 721.50K | 721.50K | 721.50K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.00M | 9.96M | 8.86M | 8.85M | 9.01M |
| Operating Income | -12.48M | -9.45M | -8.24M | -8.10M | -8.14M |
| Income Before Tax | -14.20M | -11.18M | -8.71M | -9.33M | -9.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.20 | -11.18 | -8.71 | -9.33 | -9.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 800.00 | 1.10K | 1.00K | 800.00 | 300.00 |
| Net Income | -14.20M | -11.18M | -8.71M | -9.33M | -9.13M |
| EBIT | -12.48M | -9.45M | -8.24M | -8.10M | -8.14M |
| EBITDA | -10.51M | -8.28M | -7.48M | -8.05M | -8.09M |
| EPS Basic | -3.67 | -4.50 | -4.95 | -5.83 | -6.53 |
| Normalized Basic EPS | -2.07 | -2.60 | -2.88 | -3.64 | -4.08 |
| EPS Diluted | -3.67 | -4.50 | -4.95 | -5.83 | -6.53 |
| Normalized Diluted EPS | -2.07 | -2.60 | -2.88 | -3.64 | -4.08 |
| Average Basic Shares Outstanding | 19.21M | 10.97M | 7.95M | 6.64M | 5.69M |
| Average Diluted Shares Outstanding | 19.21M | 10.97M | 7.95M | 6.64M | 5.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |